These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
47. Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectiveness. Barnes TR; Leeson VC; Paton C; Marston L; Davies L; Whittaker W; Osborn D; Kumar R; Keown P; Zafar R; Iqbal K; Singh V; Fridrich P; Fitzgerald Z; Bagalkote H; Haddad PM; Husni M; Amos T Health Technol Assess; 2017 Sep; 21(49):1-56. PubMed ID: 28869006 [TBL] [Abstract][Full Text] [Related]
48. Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone. Peuskens J; Möller HJ; Puech A Eur Neuropsychopharmacol; 2002 Aug; 12(4):305-10. PubMed ID: 12126869 [TBL] [Abstract][Full Text] [Related]
49. Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia. Barber S; Olotu U; Corsi M; Cipriani A Cochrane Database Syst Rev; 2017 Mar; 3(3):CD006324. PubMed ID: 28333365 [TBL] [Abstract][Full Text] [Related]
50. Neurophysiological evidence of impaired self-monitoring in schizotypal personality disorder and its reversal by dopaminergic antagonism. Rabella M; Grasa E; Corripio I; Romero S; Mañanas MÀ; Antonijoan RM; Münte TF; Pérez V; Riba J Neuroimage Clin; 2016; 11():770-779. PubMed ID: 27330977 [TBL] [Abstract][Full Text] [Related]
51. Individuals with psychometric schizotypy show similar social but not physical anhedonia to patients with schizophrenia. Wang Y; Lui SS; Zou LQ; Zhang Q; Zhao Q; Yan C; Hong XH; Tan SP; Cheung EF; Chan RC Psychiatry Res; 2014 May; 216(2):161-7. PubMed ID: 24589449 [TBL] [Abstract][Full Text] [Related]
52. Cognitive and oculomotor performance in subjects with low and high schizotypy: implications for translational drug development studies. Koychev I; Joyce D; Barkus E; Ettinger U; Schmechtig A; Dourish CT; Dawson GR; Craig KJ; Deakin JF Transl Psychiatry; 2016 May; 6(5):C. PubMed ID: 27187233 [TBL] [Abstract][Full Text] [Related]
53. Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study. Sechter D; Peuskens J; Fleurot O; Rein W; Lecrubier Y; Neuropsychopharmacology; 2002 Dec; 27(6):1071-81. PubMed ID: 12464464 [TBL] [Abstract][Full Text] [Related]
54. Visual information processing deficits as biomarkers of vulnerability to schizophrenia: an event-related potential study in schizotypy. Koychev I; El-Deredy W; Haenschel C; Deakin JF Neuropsychologia; 2010 Jun; 48(7):2205-14. PubMed ID: 20412812 [TBL] [Abstract][Full Text] [Related]
55. Amisulpride versus risperidone in the treatment of depression in patients with schizophrenia: a randomized, open-label, controlled trial. Kim SW; Shin IS; Kim JM; Lee SH; Lee JH; Yoon BH; Yang SJ; Hwang MY; Yoon JS Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1504-9. PubMed ID: 17692448 [TBL] [Abstract][Full Text] [Related]
56. Differential effects of olanzapine and risperidone on cognition in schizophrenia? A saccadic eye movement study. Broerse A; Crawford TJ; den Boer JA J Neuropsychiatry Clin Neurosci; 2002; 14(4):454-60. PubMed ID: 12426415 [TBL] [Abstract][Full Text] [Related]
57. SPEM dysfunction and general schizotypy as measured by the SSQ: a controlled study. van Kampen D; Deijen JB BMC Neurol; 2009 Jun; 9():27. PubMed ID: 19563649 [TBL] [Abstract][Full Text] [Related]
58. Insights to the schizophrenia continuum: A systematic review of saccadic eye movements in schizotypy and biological relatives of schizophrenia patients. Myles JB; Rossell SL; Phillipou A; Thomas E; Gurvich C Neurosci Biobehav Rev; 2017 Jan; 72():278-300. PubMed ID: 27916709 [TBL] [Abstract][Full Text] [Related]
59. Correlation between P50 suppression and psychometric schizotypy among non-clinical Japanese subjects. Wang J; Miyazato H; Hokama H; Hiramatsu K; Kondo T Int J Psychophysiol; 2004 Apr; 52(2):147-57. PubMed ID: 15050373 [TBL] [Abstract][Full Text] [Related]
60. Comparison of self-report and clinician-rated schizotypal traits in schizotypal personality disorder and community controls. Chan CC; Bulbena-Cabre A; Rutter S; Benavides C; McClure MM; Calabrese W; Rosell DR; Koenigsberg HW; Goodman M; New AS; Hazlett EA; Mercedes Perez-Rodriguez M Schizophr Res; 2019 Jul; 209():263-268. PubMed ID: 30635257 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]